Protocol for training MERGE: A federated multi-input neural network for COVID-19 prognosis.

Federated learning is a cooperative learning approach that has emerged as an effective way to address privacy concerns. Here, we present a protocol for training MERGE: a federated multi-input neural network (NN) for COVID-19 prognosis. We describe steps for collecting and preprocessing datasets. We then detail the process of training a multi-input NN. This protocol can be adapted for use with datasets containing both image- and table-based input sources. For complete details on the use and execution of this protocol, please refer to Casella et al.1.

MERGE: A model for multi-input biomedical federated learning.

Driven by the deep learning (DL) revolution, artificial intelligence (AI) has become a fundamental tool for many biomedical tasks, including analyzing and classifying diagnostic images. Imaging, however, is not the only source of information. Tabular data, such as personal and genomic data and blood test results, are routinely collected but rarely considered in DL pipelines. Nevertheless, DL requires large datasets that often must be pooled from different institutions, raising non-trivial privacy concerns. Federated learning (FL) is a cooperative learning paradigm that aims to address these issues by moving models instead of data across different institutions. Here, we present a federated multi-input architecture using images and tabular data as a methodology to enhance model performance while preserving data privacy. We evaluated it on two showcases: the prognosis of COVID-19 and patients' stratification in Alzheimer's disease, providing evidence of enhanced accuracy and F1 scores against single-input models and improved generalizability against non-federated models.

Predictors of target lesion failure after treatment of left main, bifurcation, or chronic total occlusion lesions with ultrathin-strut drug-eluting coronary stents in the ULTRA registry.

BACKGROUND: Data about the long-term performance of new-generation ultrathin-strut drug-eluting stents (DES) in challenging coronary lesions, such as left main (LM), bifurcation, and chronic total occlusion (CTO) lesions are scant. METHODS: The international multicenter retrospective observational ULTRA study included consecutive patients treated from September 2016 to August 2021 with ultrathin-strut (<70 µm) DES in challenging de novo lesions. Primary endpoint was target lesion failure (TLF): composite of cardiac death, target-lesion revascularization (TLR), target-vessel myocardial infarction (TVMI), or definite stent thrombosis (ST). Secondary endpoints included all-cause death, acute myocardial infarction (AMI), target vessel revascularization, and TLF components. TLF predictors were assessed with Cox multivariable analysis. RESULTS: Of 1801 patients (age: 66.6 ± 11.2 years; male: 1410 [78.3%]), 170 (9.4%) experienced TLF during follow-up of 3.1 ± 1.4 years. In patients with LM, CTO, and bifurcation lesions, TLF rates were 13.5%, 9.9%, and 8.9%, respectively. Overall, 160 (8.9%) patients died (74 [4.1%] from cardiac causes). AMI and TVMI rates were 6.0% and 3.2%, respectively. ST occurred in 11 (1.1%) patients while 77 (4.3%) underwent TLR. Multivariable analysis identified the following predictors of TLF: age, STEMI with cardiogenic shock, impaired left ventricular ejection fraction, diabetes, and renal dysfunction. Among the procedural variables, total stent length increased TLF risk (HR: 1.01, 95% CI: 1-1.02 per mm increase), while intracoronary imaging reduced the risk substantially (HR: 0.35, 95% CI: 0.12-0.82). CONCLUSIONS: Ultrathin-strut DES showed high efficacy and satisfactory safety, even in patients with challenging coronary lesions. Yet, despite using contemporary gold-standard DES, the association persisted between established patient- and procedure-related features of risk and impaired 3-year clinical outcome.